Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ERC2 antisense RNA 1 (ERC2-AS1) is a human long non-coding RNA gene expressed from the antisense strand overlapping the ERC2 locus[5][7]. This RNA is categorized as an antisense lncRNA, a class of transcripts that have diverse roles in gene expression regulation, commonly by interacting with chromatin modifiers or by base-pairing with sense transcripts to affect their stability, translation, or epigenetic state[1][2][10]. While many antisense lncRNAs have been implicated in development, cancer, and other diseases through gene regulation, there is currently no published functional or disease association specific to ERC2-AS1, and it is not reported as a known drug or therapeutic target[5][7]. If later structured extraction is needed, note that ERC2-AS1 fits within the class of antisense long non-coding RNAs, and its biological and therapeutic characteristics should be inferred conservatively in the absence of direct functional studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ERC2 antisense RNA 1 (ERC2-AS1).